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Abstract The need for standards in the management of
patients with endocrine tumors of the digestive system
prompted the European Neuroendocrine Tumor Society
(ENETS) to organize a first Consensus Conference, which
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Kiel, Germanywas held in Frascati (Rome) and was based on the recently
published ENETS guidelines on the diagnosis and treat-
ment of digestive neuroendocrine tumors (NET). Here, we
report the tumor–node–metastasis proposal for foregut
NETs of the stomach, duodenum, and pancreas that was
designed, discussed, and consensually approved at this
conference. In addition, we report the proposal for a
working formulation for the grading of digestive NETs
based on mitotic count and Ki-67 index. This proposal,
which needs to be validated, is meant to help clinicians in
the stratification, treatment, and follow-up of patients.
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Background
It has been known for a long time, and was finally defined
within the World Health Organization (WHO) classification
of endocrine and digestive tumors, that neuroendocrine
tumors (NET) arising at different anatomical sites of the
digestive system represent tumor entities that differ in their
biology [5, 7, 9, 31]. Several recent publications focused on
the application of the “new” WHO classification and
proved its effectiveness, supporting the concept that the
different endocrine tumor types also differ in their clinical
behavior [3, 4, 19, 20, 27, 32].
Malignant gastroenteropancreatic NETs may be fatal,
though at a significantly slower pace than their exocrine
counterparts. A number of retrospective papers and epide-
miological data solidly support such statements [8, 9, 12–
14, 21, 24, 25, 32]. This peculiar clinical feature attracted
the interest of pathologists very early and was the reason
for the special designation of such tumors as “carcinoid” by
Oberndorfer [15].
As gastroenteropancreatic NETs are rare [9, 13, 14], it is
tempting to lump them together and equate all digestive
“carcinoids” with the appendiceal “carcinoid,” probably the
best known NET with the most benign behavior [28].
However, in recent years it has become clear that gastro-
enteropancreatic NETs, especially foregut NETs, are het-
erogeneous in their morphological and biological features.
In the last two decades efforts were therefore made by the
WHO to define NET features that discriminate true benign
behavior (low risk) from low-grade malignant well-differ-
entiated NETs in the different parts of the digestive system.
Although the new WHO classification is an important step
toward defining the diverse tumor biology of NETs, further
efforts are necessary to improve the prognostic assessment
of the individual NET.
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treatment of patients with gastroenteropancreatic NETs
prompted the recently established European Neuroendo-
crine Tumor Society (ENETS) to define guidelines [22, 33].
Such guidelines underwent scrutiny for consensus in the
first of two meetings entitled “Consensus Conference on
the ENETS Guidelines for the Diagnosis and Treatment of
Neuroendocrine Gastrointestinal Tumors, Part 1: Foregut
Tumors” held in Frascati (Rome, Italy) from November
2–5, 2005. During this meeting the clinical need for a
tumor–node–metastasis (TNM) classification of gastroen-
teropancreatic NETs was felt. Here we report the TNM
staging classification proposal for foregut NETs that was
approved at this consensus conference. In addition, we
suggest a simple grading system with some pointers that
may help to standardize the prognostic assessment of
gastroenteropancreatic NETs.
Materials and methods
Sixty-two experts in the field of digestive endocrine tumors
from 20 different countries attended the Consensus Con-
ference. The attendees represented all medical branches
involved in managing patients with gastroenteropancreatic
NETs. They formed four working groups according to their
specific clinical expertise: (1) pathology and genetics (11
participants, all listed as authors and G. Klöppel), (2)
surgery (10 participants, including the coauthors H. Alhman
and M. Falconi), (3) imaging and radiology (10 participants),
(4) medicine and clinical pathology (31 participants, includ-
ing the coauthors M. Caplin, W.W. de Herder, B. Erikssson,
and B. Wiedenmann).
The Conference was divided sequentially into eight
sessions devoted to specific topics on an anatomical basis
(gastric NET sessions 1–2, duodenal NET, pancreatic NET
sessions 1–4, and poorly differentiated endocrine carcino-
mas). A working booklet with the ENETS guidelines and
specific queries had been prepared in advance by the
Organizing Committee. The work was organized such that,
after a short case presentation in a plenary session, each
working group gathered separately to discuss group-
specific questions. Once agreement was reached within
each group, consensus statements were discussed and
approved or rejected by all participants gathered in the
plenary session. This procedure was followed for all eight
sessions. The TNM staging proposal was made by the
Table 1 Proposal for a TNM classification and disease staging for gastric endocrine tumors
TNM
T—primary tumor
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
Tis In situ tumor/dysplasia (<0.5 mm)
T1 Tumor invades lamina propria or submucosa and e1c m
T2 Tumor invades muscularis propria or subserosa or >1 cm
T3 Tumor penetrates serosa
T4 Tumor invades adjacent structures
For any T, add (m) for multiple tumors
N—regional lymph nodes
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Regional lymph node metastasis
M—distant metastasis
MX Distant metastasis cannot be assessed
M0 No distant metastases
M1
a Distant metastasis
Stage
Disease stages
Stage 0 Tis N0 M0
Stage I T1 N0 M0
Stage IIa T2 N0 M0
IIb T3 N0 M0
Stage IIIa T4 N0 M0
IIIb Any T N1 M0
Stage IV Any T Any N M1
aM1 specific sites defined according to Sobin and Wittekind [29]
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approved by the plenary session of the consensus confer-
ence. The grading system was discussed and defined by the
Pathology and Genetics working group only.
Results and discussion
The consensus guidelines are reported elsewhere. Here, we
report the TNM staging proposal for gastroenteropancreatic
NETs of the foregut together with a grading system that
may be relevant for the prognostic assessment by the
pathologist. The foregut NETs were separated into gastric,
duodenal (including ampulla and proximal jejunum), and
pancreatic NETs, but were not distinguished according to
specific functional activity, main tumor cell type, and
specific genetic background.
TNM staging proposal (see Tables 1, 2 and 3)
The currently published TNM format was adopted as
working template [29].
Tumor The proposed definition of tumor in situ applies to
the stomach only and adheres to the literature [30]. No
definition is given for the duodenum and pancreas because
none has been agreed upon in spite of recent working
proposals [1, 2]. The size limits indicated for T1 are those
defined by the WHO for tumors with “benign behavior”
according to site-specific clinicopathological correlations
[5, 7, 31]. Similarly, for T2 of the stomach and duodenum,
the sizes are those indicated for tumors of “uncertain
behavior.” In the pancreas the size limit given for T2 needs
to be validated [5]. Deeply invasive tumors are included
under the T3 and T4 definitions, taking into account site-
specific features.
Nodes N1 indicates the presence of any single or multiple
metastases in regional lymph nodes, according to TNM
rules. Although the presence of regional lymph-node
metastases is, per se, a negative prognostic factor in
gastroenteropancreatic NETs [11], the prognostic signifi-
cance of the number of metastatic nodes is not known. In
light of this, stage 3B of Tables 1, 2 and 3 is proposed to
mark the N1 status for future validation.
Distant metastasis M1 indicates the presence of any single
or multiple metastases at any distant anatomical site
(including nonregional nodes). Because there is evidence
that extrahepatic bone metastases are a particularly ominous
Table 2 Proposal for a TNM classification and disease staging for endocrine tumors of the duodenum/ampulla/proximal jejunum
TNM
T—primary tumor
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
T1 Tumor invades lamina propria or submucosa and size e1c m
a
T2 Tumor invades muscularis propria or size >1 cm
T3 Tumor invades pancreas or retroperitoneum
T4 Tumor invades peritoneum or other organs
For any T, add (m) for multiple tumors
N—regional lymph nodes
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Regional lymph node metastasis
M—distant metastases
MX Distant metastasis cannot be assessed
M0 No distant metastases
M1
b Distant metastasis
Stage
Disease stages
Stage I T1 N0 M0
Stage IIa T2 N0 M0
IIb T3 N0 M0
Stage IIIa T4 N0 M0
IIIb Any T N1 M0
Stage IV Any T Any N M1
aTumor limited to ampulla of Vater for ampullary gangliocytic paraganglioma
bM1 specific sites defined according to Sobin and Wittekind [29]
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site of the metastasis according to the TNM classification rules
(PUL, pulmonary; HEP, hepatic; OSS, osseous; etc.) [29].
Staging The proposed staging system lists stage 0 only for
the stomach because this is the only anatomical site where
Tis is defined. Stage I encompasses the T1 NETs with
limited growth. Stage II identifies tumors that are larger in
size or more invasive, either T2 or T3, though always in the
absence of metastasis. At stage III the increased malignancy
refers either to invasion into surrounding structures (stage IIIa)
or to the presence of regional node metastasis (stage IIIb).
Stage IV always implies the presence of distant metastasis.
Grading proposal (see Table 4)
Grading It has been widely discussed and generally
accepted that no histological grading system effectively
predicts the behavior of well-differentiated endocrine
tumors. The major obstacle to developing a practically
effective grading system is the fact that severe cytological
atypia, as, for instance, in pheochromocytomas, has no
impact on the clinical behavior and malignancy of such
tumors. However, recent studies in well differentiated NETs
of the foregut, including the pancreas, and of the midgut
have shown the usefulness of a grading system [10, 25, 32].
Thus, well-differentiated endocrine tumors with a more
solid appearance and distinct proliferative activity, which
also lead to difficulties in the differential diagnosis vs
poorly differentiated endocrine carcinomas, seem to have a
worse prognosis than NETs without these features [16–18,
22, 23]. It was therefore decided to introduce a grading
system that could be of help in distinguishing the well-
differentiated NETs into G1 and G2 categories.
As a working suggestion, we propose to apply to foregut
NETs a grading system modified from that adopted by the
WHO for endocrine tumors of the lung, though exclusively
referring to the proliferation status. In brief (see Table 4),
three tumor categories are identified: G1, <2 mitosis per
Table 3 Proposal for a TNM classification and disease staging for endocrine tumors of the pancreas
TNM
T—primary tumor
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
T1 Tumor limited to the pancreas and size <2 cm
T2 Tumor limited to the pancreas and size 2–4c m
T3 Tumor limited to the pancreas and size >4 cm or invading duodenum or bile duct
T4 Tumor invading adjacent organs (stomach, spleen, colon, adrenal gland)
or the wall of large vessels (celiac axis or superior mesenteric artery)
For any T, add (m) for multiple tumors
N—regional lymph nodes
NX Regional lymph node cannot be assessed
N0 No regional lymph node metastasis
N1 Regional lymph node metastasis
M—distant metastases
MX Distant metastasis cannot be assessed
M0 No distant metastases
M1
a Distant metastasis
Stage
Disease stages
Stage I T1 N0 M0
Stage IIa T2 N0 M0
IIb T3 N0 M0
Stage IIIa T4 N0 M0
IIIb Any T N1 M0
Stage IV Any T Any N M1
aM1 specific sites defined according to Sobin and Wittekind [29]
Table 4 Grading proposal for foregut (neuro)endocrine tumors
Grade Mitotic count (10 HPF)
a Ki-67 index (%)
b
G1 <2 ≤2
G2 2–20 3–20
G3 >20 >20
a10 HPF: high power field=2 mm
2, at least 40 fields (at 40×
magnification) evaluated in areas of highest mitotic density
bMIB1 antibody; % of 2,000 tumor cells in areas of highest nuclear
labeling
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2 [10 high power fields (HPF) 40× magnification]
and/or Ki-67 index e2%; G2, 2–20 mitosis per 2 mm
2
and/or Ki-67 index between 3 and 20%; G3 with 21 or
more mitosis per 2 mm
2 and Ki-67 index >20%.
In general, G1 and G2 should refer to well-differentiated
NETs displaying diffuse and intense expression of the two
general immunohistochemical neuroendocrine markers,
chromogranin A and synaptophysin [26]. Punctate necrosis
is, per se, indicative of a more aggressive tumor, pointing to
a G2 status, which, however, has to be confirmed by the
mitotic count. G3 indicates a poorly differentiated neuro-
endocrine carcinoma. It has high mitotic counts/Ki-67
index, is often associated with fields of necrosis, and shows
significantly reduced chromogranin A expression, while
maintaining intense staining for synaptophysin. It is
relevant to remind here that the diagnosis of G3 carcinoma
is based on a specific histologic pattern according to the
current WHO criteria [5, 7, 31]. In addition, the clinical
behavior of G3 poorly differentiated neuroendocrine carci-
nomas of the gastroenteropancreatic tract does not neces-
sarily correspond to that of small cell cancers of the lung or
of any other sites.
Mitotic count and Ki-67 index We propose that mitoses
should be counted on hematoxylin and eosin-stained slides
in at least 40 HPFs, where possible. The mitoses should be
assessed in areas where they are most frequent after a
general slide survey. For Ki-67 assessment, the MIB1
antibody is recommended at the conditions that have been
established at the laboratory in question. The Ki-67 index
should be assessed in 2,000 tumor cells in areas where the
highest nuclear labeling is observed (often but not
exclusively at the tumor periphery).
Concluding remarks
Requests for standardization in the management of patients
with gastroenteropancreatic NETs recently resulted in the
development of several guidelines, including those pro-
posed by ENETS [16, 17, 22, 23]. However, it was never
attempted to reach consensus on specific practical issues.
The TNM staging system we propose here was developed
to meet a clinical need, is based on the current WHO
classifications of endocrine and digestive tumors, and is the
result of a consensus conference held by specialists
involved in the management of digestive endocrine tumor
patients. Along the same line, the grading system described
here attempts to close the gap between the advances of the
most recent WHO classifications and the need for a better
prognostic assessment of NETs. It is obvious, of course,
that all our proposals have to be validated by future
clinicopathological work.
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